Salih Akam K, Khozeimeh Sarbisheh Elaheh, Raheem Shvan J, Dominguez-Garcia Moralba, Mehlhorn Hillary H, Price Eric W
Department of Chemistry, College of Arts and Science, University of Saskatchewan, Saskatoon, SK, 110 Science Place, S7N-5C9, Canada.
Life Sciences Division, TRIUMF, Vancouver, BC, Canada.
Dalton Trans. 2024 Dec 3;53(47):18946-18962. doi: 10.1039/d4dt01830c.
The synthesis and evaluation of the newest generation of our DFO2 chelator family-DFO2K-is described. DFO2K was designed with a simple synthetic route to access different bifunctional derivatives, with each derivative having similar metal ion coordination spheres and high denticity (up to 12 coordinate) to ensure stable coordination of zirconium-89. The high denticity could potentially enhance stability with other large oxophilic radiometals. Zirconium-89 is the most popular radionuclide to pair with large macromolecules such as antibodies (immunoPET) for positron emission tomography applications. Although clinically successful, the stability of the "gold standard" chelator desferrioxamine B (DFO) can be improved as significant bone uptake is observed in animal models, despite no obvious stability issues in humans. Following the synthesis of DFO2K we assessed its radiolabeling efficiency with zirconium-89 and compared with DFO, which revealed rapid and nearly identical radiolabeling kinetics to DFO. The resultant [Zr]Zr-DFO2K complex showed improved stability over [Zr]Zr-DFO in different stability assays such as hydroxyapatite and 1000-fold molar excess EDTA challenges. Furthermore, biodistribution studies of the non-bifunctional chelators in healthy mice showed that [Zr]Zr-DFO2K had a similar distribution profile and clearance to [Zr]Zr-DFO. The bifunctional derivative -SCN-Ph-DFO2K was conjugated to a non-specific human IgG antibody and evaluated after 2 weeks circulating in healthy female CD1 mice. Mice administered [Zr]Zr-DFO2K-IgG showed substantially lower bone uptake in PET-CT images than [Zr]Zr-DFO-IgG, with PET ROI data and biodistribution revealing a statistically significantly lower bone uptake for DFO2K. Overall, owing to its high denticity, ease of synthesis, improved solubility over DFO2 and DFO2p, and stable chelation of zirconium-89, DFO2K appears to be an improved alternative chelator to DFO for zirconium-89 chelation.
本文描述了我们最新一代DFO2螯合剂家族——DFO2K的合成与评估。DFO2K的设计采用了简单的合成路线来制备不同的双功能衍生物,每个衍生物都具有相似的金属离子配位球和高齿合度(高达12配位),以确保与锆-89稳定配位。高齿合度可能会增强与其他大的亲氧放射性金属的稳定性。锆-89是与抗体等大分子(免疫正电子发射断层扫描)配对用于正电子发射断层扫描应用中最常用的放射性核素。尽管在临床上取得了成功,但“金标准”螯合剂去铁胺B(DFO)的稳定性仍可提高,因为在动物模型中观察到大量骨摄取,尽管在人体中没有明显的稳定性问题。在合成DFO2K后,我们评估了其与锆-89的放射性标记效率,并与DFO进行了比较,结果显示其放射性标记动力学与DFO快速且几乎相同。在不同的稳定性试验中,如羟基磷灰石和1000倍摩尔过量乙二胺四乙酸挑战试验,所得的[Zr]Zr-DFO2K配合物比[Zr]Zr-DFO表现出更好的稳定性。此外,对健康小鼠中非双功能螯合剂的生物分布研究表明,[Zr]Zr-DFO2K与[Zr]Zr-DFO具有相似的分布特征和清除率。双功能衍生物-SCN-Ph-DFO2K与非特异性人IgG抗体偶联,并在健康雌性CD1小鼠体内循环2周后进行评估。给予[Zr]Zr-DFO2K-IgG的小鼠在PET-CT图像中的骨摄取明显低于[Zr]Zr-DFO-IgG,PET感兴趣区数据和生物分布显示DFO2K的骨摄取在统计学上显著降低。总体而言,由于其高齿合度、易于合成、比DFO2和DFO2p具有更好的溶解性以及对锆-89的稳定螯合作用,DFO2K似乎是一种比DFO更好的用于锆-89螯合的替代螯合剂。